Prior studies in patients treated with PPAR‐γ agonists have shown that, despite an increase in SC fat and BW, their metabolic status was improved by treatment and more in the treatment group achieved resolution of NASH.20, 22, 23, 30, 31. Here, PPARG is linked to metabolic dysfunction-associated steatohepatitis.